What's Happening?
Colossal Biosciences Inc., a biotechnology startup valued at over $10 billion, has expanded its legal team as it pursues ambitious projects like resurrecting extinct species. The company recently hired
Albert Li, a former general counsel, to bolster its legal capabilities. Colossal's acquisition of Viagen Pets and Equine, a leading animal cloning company, coincides with high-profile investor involvement, including former NFL star Tom Brady, who used the company to clone his dog. The startup aims to leverage advances in genomics to restore biodiversity.
Why It's Important?
Colossal Biosciences' ventures into cloning and species resurrection raise significant ethical and scientific questions. The company's efforts could revolutionize conservation strategies and biodiversity restoration, potentially impacting environmental policies and scientific research. However, these initiatives also face scrutiny from ethicists concerned about the implications of genetic manipulation. The expansion of Colossal's legal team suggests a proactive approach to navigating the complex legal landscape associated with biotechnology and cloning.
